Education
About Us
Working with TipRanks
Follow Us
Universe Pharmaceuticals (UPC)
NASDAQ:UPC
Total Valuation
Universe Pharmaceuticals has a market cap or net worth of $2.49M. The enterprise value is -$21.85M.
Market Cap$2.49M
Enterprise Value-$21.85M
Share Statistics
Universe Pharmaceuticals has 563,338 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding563,338
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Universe Pharmaceuticals’s return on equity (ROE) is -0.07 and return on invested capital (ROIC) is -4.46%.
Return on Equity (ROE)-0.07
Return on Assets (ROA)-0.05
Return on Invested Capital (ROIC)-4.46%
Return on Capital Employed (ROCE)-0.05
Revenue Per Employee79.37K
Profits Per Employee-16.32K
Employee Count225
Asset Turnover0.26
Inventory Turnover5.27
Valuation Ratios
The current PE Ratio of Universe Pharmaceuticals is ―. Universe Pharmaceuticals’s PEG ratio is 0.00015.
PE Ratio―
PS Ratio0.00082
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow-0.49
PEG Ratio0.00015
Income Statement
In the last 12 months, Universe Pharmaceuticals had revenue of 17.86M and earned -3.67M in profits. Earnings per share was -1.06K.
Revenue17.86M
Gross Profit6.30M
Operating Income-2.92M
Pretax Income-3.67M
Net Income-3.67M
EBITDA-2.92M
Earnings Per Share (EPS)-1.06K
Cash Flow
In the last 12 months, operating cash flow was -5.05M and capital expenditures -266.77K, giving a free cash flow of -5.32M billion.
Operating Cash Flow-5.05M
Free Cash Flow-5.32M
Free Cash Flow per Share-9.44
Dividends & Yields
Universe Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.21
52-Week Price Change-59.17%
50-Day Moving Average4.05
200-Day Moving Average4.23
Relative Strength Index (RSI)53.98
Average Volume (3m)955.25K
Important Dates
Universe Pharmaceuticals upcoming earnings date is Feb 3, 2026, Before Open (Confirmed).
Last Earnings DateAug 4, 2025
Next Earnings DateFeb 3, 2026
Ex-Dividend Date―
Financial Position
Universe Pharmaceuticals as a current ratio of 4.07, with Debt / Equity ratio of 16.49%
Current Ratio4.07
Quick Ratio3.90
Debt to Market Cap633.71
Net Debt to EBITDA8.33
Interest Coverage Ratio-12.57
Taxes
In the past 12 months, Universe Pharmaceuticals has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Universe Pharmaceuticals EV to EBITDA ratio is 8.32, with an EV/FCF ratio of 4.50.
EV to Sales-1.36
EV to EBITDA8.32
EV to Free Cash Flow4.50
EV to Operating Cash Flow4.81
Balance Sheet
Universe Pharmaceuticals has $33.59M in cash and marketable securities with $9.26M in debt, giving a net cash position of $24.34M billion.
Cash & Marketable Securities$33.59M
Total Debt$9.26M
Net Cash$24.34M
Net Cash Per Share$43.20
Tangible Book Value Per Share$16.05K
Margins
Gross margin is 35.28%, with operating margin of -16.33%, and net profit margin of -20.56%.
Gross Margin35.28%
Operating Margin-16.33%
Pretax Margin-20.56%
Net Profit Margin-20.56%
EBITDA Margin-16.37%
EBIT Margin-19.26%
Analyst Forecast
The average price target for Universe Pharmaceuticals is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-27.81%
EPS Growth Forecast―